ICIsabelle Cloutier

Isabelle Cloutier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabelle Cloutier has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stability of Injectable Ceftobiprole Medocaril (Zevtera®) in PVC Bags and in the Intermate® Infusion System: A Technological Turning Point for Ambulatory Administration of Intravenous Antibiotics

    by Alexandra Porlier, Sylvie Pilote, Benoit Drolet, Isabelle Cloutier, Audrey Vachon, Chantale Simard

    Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.

  • Open Access

    Causality assessment of adverse events by healthcare professionals in an academic hospital setting: a descriptive retrospective study

    by Sonia Corbin, Maude Lavallée, Pallavi Pradhan, Magalie Thibault, Julie Méthot, Laura Blonde Guefack Djiokeng, Anick Bérard, Marie-Eve Piché, Fernanda Raphael Escobar Gimenes, Rosalie Darveau, et al.

    Assessing the causality of a drug product-related adverse event (AE) is a very important aspect of pharmacovigilance. However, it is unclear whether AEs are investigated for causality in a hospital setting. The aims of this study were to (1) evaluate the proportion of AEs for which causality is sought and (2) list the causality assessment (CA) tools used by healthcare professionals. This retrospective study includes 500 randomized patients (125 patients/year) admitted to a tertiary care academic hospital between 2018 and 2021. Electronic medical records were reviewed and relevant variables were extracted: (1) demographic, (2) hospitalization, (3) drug product, (4) AE, and (5) CA. A descriptive analysis was carried out (median, minimum–maximum, proportion) to characterize our sample. The characteristic of our sample was as follows: median age 69 years old (range: 21–96 years), 43.6% female, median comorbidities/patient 4 (0–12), and median hospital stay of 3 days (1–19). We identified a total of 9568 drug products and 2541 AEs, among these, 302 (8.4%) were serious AEs. No CA ( n = 0) or CA tools ( n = 0) were found in our sample. In this study, we report that no AEs, whether serious or non-serious, were subject to documented CA. Key points: Adverse events among drug users are frequent during hospital stay. Causality assessment of adverse events was poorly documented by healthcare professionals in a hospital setting.